1. Disease Information

1.1 What is MSI‑High colorectal cancer?

MSI‑H CRC is a molecular subtype of colorectal adenocarcinoma characterized by microsatellite instability (MSI), which is the tumor phenotype resulting from a deficient DNA mismatch repair (dMMR) system (parente2023thedaytodaypractice pages 2-3, ros2023immunotherapyforcolorectal pages 2-4). In practical clinical terms, CRC is classified as dMMR when immunohistochemistry (IHC) shows loss of expression of ≥1 mismatch repair proteins (MLH1, MSH2, MSH6, PMS2) (parente2023thedaytodaypractice pages 2-3, normanno2024resistancetoimmune pages 1-3). MSI itself can be detected by molecular assays (PCR or NGS) as instability at microsatellite loci (ros2023immunotherapyforcolorectal pages 2-4, fan2024oncologicalcharacteristicstreatments pages 4-5).

Abstract-supported definition (verbatim): Parente et al. (2023) describe that “Deficit in one or more MMR proteins, configuring deficient MMR status (dMMR), leads to frameshift mutations particularly clustered in microsatellite repeats. Thus, microsatellite instability (MSI) is the epiphenomenon of dMMR.” (Digestive Diseases; published May 2023; https://doi.org/10.1159/000531003) (parente2023thedaytodaypractice pages 2-3).

1.2 Common synonyms/alternative names

• dMMR CRC / MMR‑deficient CRC
• MSI/dMMR CRC
• Microsatellite instability‑high colorectal carcinoma These are used interchangeably in the reviewed sources (parente2023thedaytodaypractice pages 2-3, normanno2024resistancetoimmune pages 1-3, ros2023immunotherapyforcolorectal pages 2-4, fan2024oncologicalcharacteristicstreatments pages 4-5).

1.3 Key identifiers (availability in this run)

• MONDO: Parent disease colorectal cancer MONDO:0005575 (Open Targets mapping) (colle2023brafv600erasmutations pages 1-2)
• MeSH / ICD‑10 / ICD‑11 / Orphanet / OMIM (disease-level): not explicitly retrievable from the current evidence payload; MSI‑H CRC is primarily treated as a molecular subtype rather than a separate rare-disease entity.

1.4 Evidence source type

The synthesized disease characterization in this report is derived from aggregated disease-level resources, including multi-center trials, nationwide testing datasets, reviews, and retrospective cohort studies—not single-patient EHR narratives (parente2023thedaytodaypractice pages 2-3, colle2023brafv600erasmutations pages 1-2, fan2024oncologicalcharacteristicstreatments pages 4-5, fountzilas2024nationwiderealworlddata pages 1-2).

2. Etiology

2.1 Disease causal factors

MSI‑H CRC arises when the DNA mismatch repair system fails, due to: 1) Germline pathogenic variants in MMR genes (Lynch syndrome) (normanno2024resistancetoimmune pages 1-3, fan2024oncologicalcharacteristicstreatments pages 1-2) 2) Somatic MMR gene alterations (normanno2024resistancetoimmune pages 1-3, fan2024oncologicalcharacteristicstreatments pages 1-2) 3) Epigenetic silencing, most prominently MLH1 promoter hypermethylation, leading to loss of MLH1 (and often PMS2) protein expression (parente2023thedaytodaypractice pages 2-3, normanno2024resistancetoimmune pages 1-3, mei2022clinicopathologicalcharacteristicsof pages 6-7)

Normanno et al. (2024) explicitly state that dMMR arises from “germline/somatic mutations or epigenetic silencing (e.g., MLH1 promoter hypermethylation…)” and list core MMR proteins MSH2, MSH6, PMS2, MLH1 (published May 2024; https://doi.org/10.37349/etat.2024.00231) (normanno2024resistancetoimmune pages 1-3).

2.2 Risk factors (genetic)

• Lynch syndrome is caused by germline pathogenic variants in MLH1/MSH2/MSH6/PMS2 (and EPCAM deletions can lead to MSH2 silencing, noted in review) (normanno2024resistancetoimmune pages 1-3, fan2024oncologicalcharacteristicstreatments pages 1-2).
• Population prevalence of Lynch syndrome is reported as ~1 in 280–400 individuals (Normanno 2024) (normanno2024resistancetoimmune pages 1-3).

2.3 Risk factors (non-genetic/environmental)

The retrieved evidence in this run does not provide primary, quantitative MSI‑H‑specific environmental or lifestyle risk modifiers beyond general CRC epidemiology. This is a gap relative to the template requirements.

2.4 Protective factors / gene–environment interactions

Not directly supported by the retrieved evidence in this run.

3. Phenotypes (clinical and pathological)

3.1 Key clinicopathologic features

Across studies and reviews, MSI‑H/dMMR CRC is associated with a characteristic “immune‑rich” histopathology: - Proximal/right‑sided colon predominance (proximal localization) (dogan2024therelationshipbetween pages 1-2) - Mucinous differentiation and other histologic patterns (medullary, signet‑ring) enriched in MSI/dMMR disease (dogan2024therelationshipbetween pages 1-2) - Tumor‑infiltrating lymphocytes (TILs) and Crohn’s‑like reaction are significantly associated with dMMR in a 200‑case series (P < .001 and P = .001, respectively) (dogan2024therelationshipbetween pages 1-2)

Abstract-supported statements (verbatim/near-verbatim): In a 200‑case CRC resection cohort, Doğan et al. (2024) report significant differences in “tumor‑infiltrating lymphocytes… Crohn’s‑like reaction… mucinous differentiation… and presence of metastatic lymph nodes” between MMR‑preserved sporadic cases and Lynch candidates (published Sep 2024; https://doi.org/10.5152/tjg.2024.23366) (dogan2024therelationshipbetween pages 1-2).

3.2 Phenotype characteristics (onset, progression, frequency)

• Frequency among CRC: MSI/dMMR comprises about 15% of CRC overall in several reviews (normanno2024resistancetoimmune pages 1-3, fan2024oncologicalcharacteristicstreatments pages 1-2).
• Stage distribution (enrichment in earlier stages): about 20% in stage I–II, ~13% in stage III, and ~4–5% in stage IV/metastatic CRC (normanno2024resistancetoimmune pages 1-3). Another 2024 review summarizes ~20% in stage II, ~12% in stage III, and ~4% in stage IV (fan2024oncologicalcharacteristicstreatments pages 1-2).

3.3 Suggested HPO terms (examples)

Because MSI‑H CRC is a tumor subtype, phenotype capture often maps to neoplastic and histopathologic features rather than symptoms. Suggested HPO terms include: - Colorectal carcinoma (HP:0003003; commonly used for colorectal cancer phenotyping) - Mucinous adenocarcinoma (HPO term exists for mucinous carcinoma phenotypes; confirm exact ID during curation) - Increased tumor-infiltrating lymphocytes (no single universal HPO term; may be represented via pathology annotations rather than HPO)

Note: Exact HPO identifiers for histopathology descriptors should be validated against the current HPO release; the present run did not include an HPO lookup tool.

4. Genetic/Molecular Information

4.1 Causal genes (core MMR machinery)

Core genes repeatedly cited: - MLH1, MSH2, MSH6, PMS2 (parente2023thedaytodaypractice pages 2-3, normanno2024resistancetoimmune pages 1-3, fan2024oncologicalcharacteristicstreatments pages 1-2)

These correspond to proteins assessed by IHC to define dMMR in routine clinical practice (parente2023thedaytodaypractice pages 2-3, ros2023immunotherapyforcolorectal pages 2-4).

4.2 Pathogenic variant classes and origin

• Germline (Lynch syndrome): pathogenic/likely pathogenic variants in MMR genes (normanno2024resistancetoimmune pages 1-3)
• Somatic/epigenetic (sporadic MSI‑H CRC): MLH1 promoter hypermethylation and somatic MMR alterations (normanno2024resistancetoimmune pages 1-3, fan2024oncologicalcharacteristicstreatments pages 1-2)

4.3 Epigenetic information

• MLH1 promoter hypermethylation is a major mechanism for sporadic MSI‑H CRC (normanno2024resistancetoimmune pages 1-3, fan2024oncologicalcharacteristicstreatments pages 1-2).
• A narrative review excerpt reports that ~80% of dMMR CRCs show MLH1 promoter methylation (mei2022clinicopathologicalcharacteristicsof pages 6-7).

4.4 Molecular profiling / immune microenvironment

MSI‑H/dMMR CRC is described as hypermutated, yielding more neoantigens and an immune‑inflamed microenvironment with immune checkpoint upregulation, supporting response to PD‑1/PD‑L1 and CTLA‑4 blockade (parente2023thedaytodaypractice pages 2-3, normanno2024resistancetoimmune pages 1-3, ros2023immunotherapyforcolorectal pages 2-4).

4.5 Suggested GO (process) and CL (cell type) terms

Based on the mechanistic chain (dMMR → frameshift mutations → neoantigens → T‑cell infiltration → checkpoint upregulation): - GO biological processes (suggestions): DNA mismatch repair; response to DNA damage stimulus; antigen processing and presentation (MHC class I); T cell activation; interferon‑gamma signaling. - Cell Ontology (CL) suggestions: cytotoxic T cell (CD8+ T cell); T helper 1 cell; tumor-associated macrophage.

Note: Exact GO/CL IDs should be validated during curation; the run did not include ontology lookup tooling.

5. Environmental Information

MSI‑H CRC is defined by tumor DNA repair biology and is most directly linked to genetic/epigenetic mechanisms. The retrieved evidence does not provide MSI‑H‑specific environmental toxicant, infectious, or lifestyle causation signals. This section should be populated from dedicated epidemiologic literature (not captured here).

6. Mechanism / Pathophysiology

6.1 Causal chain (current understanding)

1) Upstream trigger: loss of function in MMR (germline mutation, somatic mutation, or MLH1 promoter hypermethylation) (normanno2024resistancetoimmune pages 1-3, fan2024oncologicalcharacteristicstreatments pages 1-2) 2) Genomic consequence: accumulation of insertion/deletion errors at microsatellite repeats → frameshift mutations (parente2023thedaytodaypractice pages 2-3) 3) Immunogenic consequence: high tumor mutational burden and frameshift-derived neoantigens → increased immune infiltration and checkpoint expression (PD‑1/PD‑L1/CTLA‑4) (parente2023thedaytodaypractice pages 2-3, normanno2024resistancetoimmune pages 1-3, ros2023immunotherapyforcolorectal pages 2-4) 4) Therapeutic implication: strong rationale for immune checkpoint blockade; however, a subset (~30%) exhibit primary resistance to single-agent PD‑1 therapy (normanno2024resistancetoimmune pages 1-3).

6.2 Upstream vs downstream

• Upstream: MLH1 methylation; germline/somatic MMR gene alterations (normanno2024resistancetoimmune pages 1-3)
• Downstream: hypermutation/neoantigen burden; immune cell infiltration; checkpoint expression; treatment sensitivity/resistance patterns (normanno2024resistancetoimmune pages 1-3, ros2023immunotherapyforcolorectal pages 2-4)

7. Anatomical Structures Affected

7.1 Organ level

• Primary organ system: large intestine (colon and rectum); MSI‑H/dMMR is enriched in proximal/right-sided colon in observational pathology cohorts (dogan2024therelationshipbetween pages 1-2).

7.2 Tissue/cell level

• Primary tissue: colonic/rectal epithelium (glandular epithelium) giving rise to adenocarcinoma.
• Immune microenvironment: increased TILs (dogan2024therelationshipbetween pages 1-2).

7.3 Suggested UBERON terms

• Colon (e.g., UBERON:0001155) and subregions such as ascending colon (right/proximal)

Note: Exact IDs should be validated during curation.

8. Temporal Development

• MSI‑H/dMMR is more prevalent in early-stage/localized CRC (stage I–II) than metastatic CRC (stage IV), consistent with reduced representation among metastatic cases (normanno2024resistancetoimmune pages 1-3, fan2024oncologicalcharacteristicstreatments pages 1-2).

The retrieved evidence does not provide a formal natural-history staging timeline beyond stage distribution; additional longitudinal registry studies would be needed.

9. Inheritance and Population

9.1 Epidemiology (proportion of CRC that is MSI‑H/dMMR)

• ~15% of CRC overall are dMMR/MSI (normanno2024resistancetoimmune pages 1-3).
• Stage-specific distribution: ~20% in stage I–II, ~13% in stage III, ~4–5% in stage IV (normanno2024resistancetoimmune pages 1-3).

9.2 Hereditary contribution and Lynch syndrome

• Approximately ~3% of all CRC are attributed to germline MMR mutations in the Normanno review excerpt (normanno2024resistancetoimmune pages 1-3).
• Among MSI/dMMR CRC, about ~20% are Lynch syndrome-related in Parente et al. (2023) (parente2023thedaytodaypractice pages 2-3).

10. Diagnostics

10.1 Clinical/pathology tests

Primary diagnostic modalities: - MMR IHC (MLH1/MSH2/MSH6/PMS2): loss of one or more proteins defines dMMR (parente2023thedaytodaypractice pages 2-3). - PCR-based MSI: recommended pentaplex marker sets and instability thresholds (ros2023immunotherapyforcolorectal pages 2-4). - NGS-based MSI: increasingly used; can outperform some algorithms especially in low tumor purity settings (not fully explored in retrieved evidence, but NGS use and specimen constraints are noted) (fan2024oncologicalcharacteristicstreatments pages 4-5).

Performance / discordance: - IHC and PCR concordance reported ~90–97% in CRC (ros2023immunotherapyforcolorectal pages 2-4). - Discordance reported around 1–10% in one 2024 review excerpt; under standardized conditions, a positive result from either test can be used to justify ICI use (fan2024oncologicalcharacteristicstreatments pages 4-5). - In a nationwide real‑world Greek dataset, among tumors tested by both approaches, overall discordance was 2.3% (21/904) (published May 2024; https://doi.org/10.3390/diagnostics14111076) (fountzilas2024nationwiderealworlddata pages 1-2).

10.2 Sporadic vs Lynch syndrome triage (MLH1 loss workup)

A standard discriminatory concept in the retrieved sources is: - Sporadic dMMR/MSI‑H CRC: often MLH1 promoter hypermethylation, with BRAF V600E frequently present (normanno2024resistancetoimmune pages 1-3, mei2022clinicopathologicalcharacteristicsof pages 6-7). - Hereditary (Lynch) suspicion: absence of BRAF mutation and absence of MLH1 methylation raise suspicion for Lynch syndrome (mei2022clinicopathologicalcharacteristicsof pages 6-7).

In the ICI-treated metastatic cohort analysis by Colle et al. (2023), “sporadic” was operationalized as loss of MLH1/PMS2 with BRAFV600E and/or MLH1 promoter hypermethylation, or biallelic somatic MMR mutations, while Lynch required a detected germline MMR mutation (published Apr 2023; https://doi.org/10.1093/oncolo/oyad082) (colle2023brafv600erasmutations pages 1-2).

10.3 Suggested differential diagnosis considerations

The main practical differential is false-positive/false-negative MSI/dMMR testing due to assay pitfalls or tumor heterogeneity; misdiagnosis is explicitly discussed as a contributor to apparent ICI “resistance” (normanno2024resistancetoimmune pages 1-3).

11. Outcome / Prognosis

The retrieved evidence emphasizes predictive/prognostic implications rather than registry-derived survival by stage. - MSI/dMMR CRC can show resistance to 5‑FU in some contexts and strong sensitivity to immune checkpoint blockade (parente2023thedaytodaypractice pages 2-3). - A subset of metastatic MSI‑H/dMMR CRC (up to ~30%) can show progressive disease on single-agent PD‑1 therapy (normanno2024resistancetoimmune pages 1-3).

For comprehensive long-term prognosis (5‑year OS by stage), SEER/registry sources are needed and were not included in this run.

12. Treatment

12.1 Immunotherapy (current real-world implementation)

Metastatic setting - KEYNOTE‑177 (NCT02563002): Pembrolizumab as first-line therapy improved PFS vs chemotherapy. Colle et al. cite median PFS 16.5 vs 8.2 months (HR 0.60, 95% CI 0.45–0.80; P=.0002) (colle2023brafv600erasmutations pages 1-2). A 2023 review table reports ORR 43.8%, including CR 11.1% and PR 32.7%, with median PFS ~16.5 months (ros2023immunotherapyforcolorectal pages 2-4). - CheckMate‑142 (previously treated mCRC): Nivolumab monotherapy ORR 31.1% (phase II; n=74) as summarized in Normanno 2024 (normanno2024resistancetoimmune pages 1-3).

Real-world comparative effectiveness: A clinicogenomic cohort (Foundation Medicine testing across ~280 US clinics) reported in 138 MSI‑H mCRC patients that first‑line ICIs vs chemotherapy had median PFS 24.87 vs 5.65 months (AHR 0.31) and OS not reached vs 24.1 months (HR 0.45) (quintanilha2023comparativeeffectivenessof pages 1-2).

12.2 Neoadjuvant immunotherapy (2023–2024 development highlight)

Neoadjuvant ICI for localized dMMR/MSI‑H colon cancer has shown striking pathologic regression: - NICHE‑2: MPR 95%, pCR 68% in a 2024 review excerpt (fan2024oncologicalcharacteristicstreatments pages 4-5). - NICHE‑3 (Nature Medicine 2024; NCT03026140): Nivolumab + relatlimab (anti‑PD‑1 + anti‑LAG‑3) achieved pathologic response 97% (57/59), MPR 92%, and pCR 68% (40/59), with grade 3–4 immune‑related adverse events 10% (https://doi.org/10.1038/s41591-024-03250-w) (gooyer2024neoadjuvantnivolumaband media 4e5d7e56, gooyer2024neoadjuvantnivolumaband media 37cc97ed, gooyer2024neoadjuvantnivolumaband media 1ac973b3, gooyer2024neoadjuvantnivolumaband media 592f02c3).

12.3 Treatment ontology (MAXO) suggestions

• Immune checkpoint inhibitor therapy (anti‑PD‑1; anti‑CTLA‑4; anti‑LAG‑3)
• Neoadjuvant immunotherapy
• Surgical resection (colectomy/proctectomy)

Note: Exact MAXO IDs should be curated separately.

12.4 Ongoing trials (examples from ClinicalTrials.gov search)

The trial search retrieved multiple active studies of neoadjuvant/adjuvant PD‑1–based strategies in dMMR/MSI‑H colorectal cancer (e.g., NCT04643041 watch‑and‑wait distal rectal cancer; NCT06520683 adjuvant PD‑1 blockade high-risk stage II; NCT03926338 toripalimab ± celecoxib) (clinical trial tool output; not individually evidenced in text snippets in this run).

13. Prevention

No MSI‑H‑specific primary prevention strategies are evidenced in the retrieved corpus beyond the implicit prevention of Lynch-associated cancers via identification and surveillance. A complete prevention section would require guideline sources (e.g., USPSTF, NCCN) not included in the tool-evidence payload.

14. Other Species / Natural Disease

No non-human naturally occurring MSI‑H CRC evidence was retrieved in this run.

15. Model Organisms

15.1 MSI‑H/dMMR-specific model systems (2023 example)

Song et al. (Frontiers in Oncology 2023; https://doi.org/10.3389/fonc.2023.1223915) report: - Organoids derived from intestine tumors in an Msh2-deficient mouse model, with MSI‑H and high frameshift mutation frequency. - An orthotopic intra‑cecal implantation model from organoid-derived tumor fragments showing progressive growth and distant metastasis to liver and lymph node, forming adenocarcinomas “mixed with mucinous features.” The authors propose suitability for testing neoantigen-based vaccines and combination therapies (song2023organoidsandmetastatic pages 1-2).

Summary Table (quantitative quick reference)

Table: This table compiles the main definitions, prevalence estimates, diagnostic thresholds, and headline immunotherapy outcomes for MSI-high/dMMR colorectal cancer from the gathered evidence. It is useful as a quick-reference summary for knowledge base population and citation tracking.

Recent developments and expert analysis (2023–2024 prioritized)

1) Neoadjuvant immunotherapy is rapidly moving from proof-of-concept toward broader clinical testing in localized dMMR colon cancer, with NICHE‑3 (2024) demonstrating very high pathologic response rates and manageable grade 3–4 irAEs at 10% (gooyer2024neoadjuvantnivolumaband media 4e5d7e56, gooyer2024neoadjuvantnivolumaband media 37cc97ed). 2) Diagnostic accuracy and correct classification (sporadic vs Lynch; true MSI/dMMR vs assay artifact) are emphasized as prerequisites for optimal immunotherapy selection, and misdiagnosis is explicitly raised as a cause of early ICI progression in MSI/dMMR mCRC (normanno2024resistancetoimmune pages 1-3). 3) Real-world data show growing MSI/MMR testing uptake and high but not perfect concordance between IHC and MSI methods (2.3% discordance in a nationwide dataset) (fountzilas2024nationwiderealworlddata pages 1-2).

Gaps relative to the template (not supported by retrieved evidence here)

• Formal MeSH/ICD‑10/ICD‑11 codes and a MONDO ID specific to “MSI‑H colorectal cancer” subtype.
• MSI‑H‑specific environmental/lifestyle risk modifiers and protective factors.
• Comprehensive survival statistics (e.g., 5‑year OS) from cancer registries.
• POLE/POLD1-driven “ultramutated” CRC data within the retrieved evidence set.

These items can be filled by targeted retrieval from guideline/registry/ontology resources in a subsequent run.

References

1. (colle2023brafv600erasmutations pages 1-2): Raphael Colle, Sara Lonardi, Marine Cachanado, Michael J Overman, Elena Elez, Marwan Fakih, Francesca Corti, Priya Jayachandran, Magali Svrcek, Antoine Dardenne, Baptiste Cervantes, Alex Duval, Romain Cohen, Filippo Pietrantonio, and Thierry André. Braf v600e/ras mutations and lynch syndrome in patients with msi-h/dmmr metastatic colorectal cancer treated with immune checkpoint inhibitors. The Oncologist, 28:771-779, Apr 2023. URL: https://doi.org/10.1093/oncolo/oyad082, doi:10.1093/oncolo/oyad082. This article has 41 citations.

2. (parente2023thedaytodaypractice pages 2-3): Paola Parente, Federica Grillo, Alessandro Vanoli, Maria Cristina Macciomei, Maria Raffaella Ambrosio, Nunzia Scibetta, Emanuela Filippi, Ivana Cataldo, Luigi Baron, Giuseppe Ingravallo, Gerardo Cazzato, Laura Melocchi, Barbara Liserre, Carla Giordano, Graziana Arborea, Emanuela Pilozzi, Antonio Scapinello, Maria Costanza Aquilano, Roberta Gafà, Serena Battista, Luca Dal Santo, Michela Campora, Francesco Giuseppe Carbone, Chiara Sartori, Stefano Lazzi, Ester Hanspeter, Valentina Angerilli, Luca Mastracci, and Matteo Fassan. The day-to-day practice of mmr and msi assessment in colorectal adenocarcinoma: what we know and what we still need to explore. Digestive Diseases, 41:746-756, May 2023. URL: https://doi.org/10.1159/000531003, doi:10.1159/000531003. This article has 48 citations and is from a peer-reviewed journal.

3. (ros2023immunotherapyforcolorectal pages 2-4): Javier Ros, Iosune Baraibar, Nadia Saoudi, Marta Rodriguez, Francesc Salvà, Josep Tabernero, and Elena Élez. Immunotherapy for colorectal cancer with high microsatellite instability: the ongoing search for biomarkers. Cancers, 15:4245, Aug 2023. URL: https://doi.org/10.3390/cancers15174245, doi:10.3390/cancers15174245. This article has 53 citations.

4. (normanno2024resistancetoimmune pages 1-3): Nicola Normanno, Vincenza Caridi, Matteo Fassan, Antonio Avallone, Fortunato Ciardiello, and Carmine Pinto. Resistance to immune checkpoint inhibitors in colorectal cancer with deficient mismatch repair/microsatellite instability: misdiagnosis, pseudoprogression and/or tumor heterogeneity? Exploration of Targeted Anti-tumor Therapy, 5:495-507, May 2024. URL: https://doi.org/10.37349/etat.2024.00231, doi:10.37349/etat.2024.00231. This article has 7 citations.

5. (fan2024oncologicalcharacteristicstreatments pages 4-5): Wen-Xuan Fan, Fei Su, Yan Zhang, Xiao-Ling Zhang, Yun-Yi Du, Yang-Jun Gao, Wei-Ling Li, Wen-Qing Hu, and Jun Zhao. Oncological characteristics, treatments and prognostic outcomes in mmr-deficient colorectal cancer. Biomarker Research, Aug 2024. URL: https://doi.org/10.1186/s40364-024-00640-7, doi:10.1186/s40364-024-00640-7. This article has 27 citations and is from a peer-reviewed journal.

6. (fountzilas2024nationwiderealworlddata pages 1-2): Elena Fountzilas, Theofanis Papadopoulos, Eirini Papadopoulou, Cedric Gouedard, Helen P. Kourea, Pantelis Constantoulakis, Christina Magkou, Maria Sfakianaki, Vassiliki Kotoula, Dimitra Bantouna, Georgia Raptou, Angelica A. Saetta, Georgia Christopoulou, Dimitris Hatzibougias, Electra Michalopoulou-Manoloutsiou, Eleni Siatra, Eleftherios Eleftheriadis, Evangelia Kavoura, Loukas Kaklamanis, Antigoni Sourla, George Papaxoinis, Kitty Pavlakis, Prodromos Hytiroglou, Christina Vourlakou, Petroula Arapantoni-Dadioti, Samuel Murray, George Nasioulas, Grigorios Timologos, George Fountzilas, and Zacharenia Saridaki. Nationwide real-world data of microsatellite instability and/or mismatch repair deficiency in cancer: prevalence and testing patterns. Diagnostics, 14:1076, May 2024. URL: https://doi.org/10.3390/diagnostics14111076, doi:10.3390/diagnostics14111076. This article has 4 citations.

7. (fan2024oncologicalcharacteristicstreatments pages 1-2): Wen-Xuan Fan, Fei Su, Yan Zhang, Xiao-Ling Zhang, Yun-Yi Du, Yang-Jun Gao, Wei-Ling Li, Wen-Qing Hu, and Jun Zhao. Oncological characteristics, treatments and prognostic outcomes in mmr-deficient colorectal cancer. Biomarker Research, Aug 2024. URL: https://doi.org/10.1186/s40364-024-00640-7, doi:10.1186/s40364-024-00640-7. This article has 27 citations and is from a peer-reviewed journal.

8. (mei2022clinicopathologicalcharacteristicsof pages 6-7): Wei-Jian Mei, Mi Mi, Jing Qian, Nan Xiao, Ying Yuan, and Pei-Rong Ding. Clinicopathological characteristics of high microsatellite instability/mismatch repair-deficient colorectal cancer: a narrative review. Frontiers in Immunology, Dec 2022. URL: https://doi.org/10.3389/fimmu.2022.1019582, doi:10.3389/fimmu.2022.1019582. This article has 73 citations and is from a peer-reviewed journal.

9. (dogan2024therelationshipbetween pages 1-2): Mehmet Doğan, Mehmet Kılıç, and Hayriye Tatlı Doğan. The relationship between dna mismatch repair status and clinicopathologic characteristics in colon cancer. Turkish Journal of Gastroenterology, 35:718-725, Sep 2024. URL: https://doi.org/10.5152/tjg.2024.23366, doi:10.5152/tjg.2024.23366. This article has 3 citations and is from a peer-reviewed journal.

10. (quintanilha2023comparativeeffectivenessof pages 1-2): JCF Quintanilha, RP Graf, and VA Fisher. Comparative effectiveness of immune checkpoint inhibitors vs chemotherapy in patients with metastatic colorectal cancer with measures of microsatellite instability …. Unknown journal, 2023.

11. (gooyer2024neoadjuvantnivolumaband media 4e5d7e56): Peter G. M. de Gooyer, Yara L. Verschoor, Lauren D. W. van den Dungen, Sara Balduzzi, Hendrik A. Marsman, Marnix H. Geukes Foppen, Cecile Grootscholten, Simone Dokter, Anne G. den Hartog, Wieke H. M. Verbeek, Karlijn Woensdregt, Joris J. van den Broek, Steven J. Oosterling, Ton N. Schumacher, Koert F. D. Kuhlmann, Regina G. H. Beets-Tan, John B. A. G. Haanen, Monique E. van Leerdam, Jose G. van den Berg, and Myriam Chalabi. Neoadjuvant nivolumab and relatlimab in locally advanced mmr-deficient colon cancer: a phase 2 trial. Nature Medicine, 30:3284-3290, Sep 2024. URL: https://doi.org/10.1038/s41591-024-03250-w, doi:10.1038/s41591-024-03250-w. This article has 100 citations and is from a highest quality peer-reviewed journal.

12. (gooyer2024neoadjuvantnivolumaband media 37cc97ed): Peter G. M. de Gooyer, Yara L. Verschoor, Lauren D. W. van den Dungen, Sara Balduzzi, Hendrik A. Marsman, Marnix H. Geukes Foppen, Cecile Grootscholten, Simone Dokter, Anne G. den Hartog, Wieke H. M. Verbeek, Karlijn Woensdregt, Joris J. van den Broek, Steven J. Oosterling, Ton N. Schumacher, Koert F. D. Kuhlmann, Regina G. H. Beets-Tan, John B. A. G. Haanen, Monique E. van Leerdam, Jose G. van den Berg, and Myriam Chalabi. Neoadjuvant nivolumab and relatlimab in locally advanced mmr-deficient colon cancer: a phase 2 trial. Nature Medicine, 30:3284-3290, Sep 2024. URL: https://doi.org/10.1038/s41591-024-03250-w, doi:10.1038/s41591-024-03250-w. This article has 100 citations and is from a highest quality peer-reviewed journal.

13. (gooyer2024neoadjuvantnivolumaband media 1ac973b3): Peter G. M. de Gooyer, Yara L. Verschoor, Lauren D. W. van den Dungen, Sara Balduzzi, Hendrik A. Marsman, Marnix H. Geukes Foppen, Cecile Grootscholten, Simone Dokter, Anne G. den Hartog, Wieke H. M. Verbeek, Karlijn Woensdregt, Joris J. van den Broek, Steven J. Oosterling, Ton N. Schumacher, Koert F. D. Kuhlmann, Regina G. H. Beets-Tan, John B. A. G. Haanen, Monique E. van Leerdam, Jose G. van den Berg, and Myriam Chalabi. Neoadjuvant nivolumab and relatlimab in locally advanced mmr-deficient colon cancer: a phase 2 trial. Nature Medicine, 30:3284-3290, Sep 2024. URL: https://doi.org/10.1038/s41591-024-03250-w, doi:10.1038/s41591-024-03250-w. This article has 100 citations and is from a highest quality peer-reviewed journal.

14. (gooyer2024neoadjuvantnivolumaband media 592f02c3): Peter G. M. de Gooyer, Yara L. Verschoor, Lauren D. W. van den Dungen, Sara Balduzzi, Hendrik A. Marsman, Marnix H. Geukes Foppen, Cecile Grootscholten, Simone Dokter, Anne G. den Hartog, Wieke H. M. Verbeek, Karlijn Woensdregt, Joris J. van den Broek, Steven J. Oosterling, Ton N. Schumacher, Koert F. D. Kuhlmann, Regina G. H. Beets-Tan, John B. A. G. Haanen, Monique E. van Leerdam, Jose G. van den Berg, and Myriam Chalabi. Neoadjuvant nivolumab and relatlimab in locally advanced mmr-deficient colon cancer: a phase 2 trial. Nature Medicine, 30:3284-3290, Sep 2024. URL: https://doi.org/10.1038/s41591-024-03250-w, doi:10.1038/s41591-024-03250-w. This article has 100 citations and is from a highest quality peer-reviewed journal.

15. (song2023organoidsandmetastatic pages 1-2): Yurong Song, Travis D. Kerr, Chelsea Sanders, Lisheng Dai, Shaneen S. Baxter, Brandon Somerville, Ryan N. Baugher, Stephanie D. Mellott, Todd B. Young, Heidi E. Lawhorn, Teri M. Plona, Bingfang Xu, Lei Wei, Qiang Hu, Song Liu, Alan Hutson, Baktiar Karim, Sandra Burkett, Simone Difilippantonio, Ligia Pinto, Johannes Gebert, Matthias Kloor, Steven M. Lipkin, Shizuko Sei, and Robert H. Shoemaker. Organoids and metastatic orthotopic mouse model for mismatch repair-deficient colorectal cancer. Frontiers in Oncology, Sep 2023. URL: https://doi.org/10.3389/fonc.2023.1223915, doi:10.3389/fonc.2023.1223915. This article has 10 citations.